| 1 |
NCT02534402 |
Active, not recruiting |
Prednisone Administration in Quiescent COPD Patients to Determine the Effect on Gene Expression |
- Chronic Obstructive Pulmonary Disease
|
|
Interventional
|
Phase 4 |
- University of British Columbia
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Effect of prednisone on peripheral whole blood gene expression
|
40 |
All |
19 Years to 95 Years (Adult, Older Adult) |
NCT02534402 |
H15-01147 |
|
August 2015 |
December 2016 |
December 2017 |
August 27, 2015 |
May 31, 2017 |
|
- St. Paul's Hospital
Vancouver, British Columbia, Canada
|
|
| 2 |
NCT02689960 |
Completed |
Vaginal Prednisone Administration for Prevention of Adrenal Crisis |
|
- Drug: 100mg prednisone suppository
|
Interventional
|
Phase 2 |
- Wuerzburg University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Bioequivalence of vaginal prednisone administration compared to rectal application, assessed by repeated determination of prednisolon levels (in blood)
- Safety of the vaginal administration of prednisone compared to rectal application, assessed by the number of participants with treatment-related adverse events (using the NCI-CTC, version 4.0).
- Suppressive effects on ACTH levels after vaginal administration of prednisone compared to rectal application, assessed by repeated determination of ACTH-levels
- Tolerability by the patients assessed by a questionnaire
|
12 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02689960 |
Vapreda |
Vapreda |
January 2017 |
April 2017 |
June 1, 2017 |
February 24, 2016 |
June 20, 2017 |
|
|
|
| 3 |
NCT01933724 |
Recruiting |
The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach |
- Granulomatosis With Polyangiitis
- Wegener Granulomatosis
- Vasculitis
|
- Drug: 5 mg prednisone
- Drug: 0 mg prednisone
|
Interventional
|
Phase 3 |
- University of South Florida
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
- (and 4 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Prednisone dose increase for disease relapse
- Rates of disease flare sub types
- Time to event flare
- (and 3 more...)
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT01933724 |
VCRC 5526B TAPIR
5526B
R01HL115041 |
TAPIR |
February 2014 |
June 2019 |
June 2019 |
September 2, 2013 |
October 11, 2018 |
|
- University of South Florida TAPIR Study Team
Tampa, Florida, United States
|
|
| 4 |
NCT02479490 |
Terminated |
PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI |
|
- Drug: Prednisone + Everolimus
|
Interventional
|
Phase 2 |
- Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- safety and tolerability evaluation (incidence of grade ≥ 2 stomatitis and non-infectious pneumonitis)
- Overall response rate (ORR)
- Progression free survival (PFS)
- Overall survival (OS)
|
8 |
All |
18 Years and older (Adult, Older Adult) |
NCT02479490 |
IRST189.04 |
PREV |
September 22, 2015 |
May 5, 2017 |
September 2017 |
June 24, 2015 |
January 16, 2018 |
|
- U.O Oncologia Medica, IRST IRCCS
Meldola, FC, Italy - Oncologia Medica, PO Faenza, AUSL della Romagna
Faenza, RA, Italy - Oncologia Medica, PO RAVENNA, AUSL della Romagna
Ravenna, RA, Italy - Oncologia Medica, PO Rimini-Cattolica, AUSL della Romagna
Rimini, Italy
|
|
| 5 |
NCT02702778 |
Terminated |
Delayed Release Prednisone in PMR |
|
- Drug: Delayed-Release (DR) Prednisone
- Drug: Immediate Release (IR) Prednisone
|
Interventional
|
Phase 2 |
- Dinora, Inc.
- Analgesic Solutions
- PharPoint Research, Inc.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change of the severity of morning stiffness from baseline to end of study (28days)
- Relative reduction in the duration of morning stiffness (minutes)
- Relative IL-6 treatment response.
- (and 3 more...)
|
8 |
All |
50 Years and older (Adult, Older Adult) |
NCT02702778 |
HZNP-PRE-IIS02 |
|
February 2016 |
December 31, 2016 |
March 31, 2017 |
March 9, 2016 |
May 3, 2017 |
|
- Clinical Research Site
Miami, Florida, United States - Clinical Research Site
Mineola, New York, United States - Clinical Research Site
Duncansville, Pennsylvania, United States - (and 3 more...)
|
|
| 6 |
NCT03726749 |
Recruiting |
Tocilizumab Plus a Short Prednisone Taper for GCA |
|
- Drug: Tocilizumab
- Drug: Prednisone
|
Interventional
|
Phase 4 |
- Massachusetts General Hospital
- Roche-Genentech
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Sustained remission
- Number of disease flares
- Cumulative prednisone dose
- (and 2 more...)
|
30 |
All |
50 Years and older (Adult, Older Adult) |
NCT03726749 |
ML40859 |
|
November 28, 2018 |
December 2021 |
February 2022 |
October 31, 2018 |
November 30, 2018 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 7 |
NCT01821040 |
Terminated |
A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR |
|
- Drug: Lodotra®
- Drug: Prednisone IR (immediate release)
|
Interventional
|
Phase 3 |
- Mundipharma Research Limited
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- To show that treatment with Lodotra® is noninferior to treatment with prednisone IR with regards to the percentage of complete responders.
- Patient reported outcomes
|
62 |
All |
50 Years and older (Adult, Older Adult) |
NCT01821040 |
LOD3501
2011-002353-57 |
|
March 2013 |
April 2014 |
April 2014 |
March 29, 2013 |
October 24, 2018 |
|
- Southend University Hospital
Westcliff on Sea, United Kingdom
|
|
| 8 |
NCT02274402 |
Completed |
Pharmacokinetics of Prednisone in Adults |
- Patients Receiving Prednisone
|
- Biological: blood sampling
|
Observational
|
|
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- composite Pharmacokinetic parameter for Prednisone
- Side effects
|
114 |
All |
Child, Adult, Older Adult |
NCT02274402 |
2014-A00926-41 |
Glucomad |
November 2014 |
November 2015 |
June 2016 |
October 24, 2014 |
August 2, 2016 |
|
- AP-HP Cochin
Paris, France
|
|
| 9 |
NCT00580229 |
Completed
Has Results |
A Safety Analysis of Oral Prednisone as a Pre-Treatment for Rituximab in Rheumatoid Arthritis. |
|
|
Interventional
|
Phase 2
Phase 3 |
- University of South Florida
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Acute Infusion Reactions in the First 24 Hours After Oral Prednisone Pretreatment to Initial Rituximab Infusion
- Adverse Infusion Reactions Within 24 Hours Following the Second Rituximab Infusion.
- Adverse Events Assessed From Day 15 Through Week 26.
|
50 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT00580229 |
U4164s |
|
December 2007 |
December 2010 |
December 2011 |
December 24, 2007 |
July 26, 2018 |
October 4, 2016 |
- Arthritis Research of Florida, Inc.
Palm Harbor, Florida, United States - University of South Florida
Tampa, Florida, United States
|
|
| 10 |
NCT01940094 |
Recruiting |
The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach |
- Granulomatosis With Polyangiitis
|
- Drug: 5 mg Prednisone
- Drug: 0 mg Prednisone
|
Interventional
|
Phase 3 |
- University of Pennsylvania
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- (and 3 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Physician decision to increase glucocorticoids for disease relapse.
- Time to disease flare.
- Safety outcomes.
- (and 3 more...)
|
159 |
All |
18 Years and older (Adult, Older Adult) |
NCT01940094 |
VCRC5526A
R01HL115041
U54AR057319 |
TAPIR |
February 2014 |
September 2019 |
December 2019 |
September 11, 2013 |
October 19, 2018 |
|
- Boston University
Boston, Massachusetts, United States - Mayo Clinic
Rochester, Minnesota, United States - Cleveland Clinic
Cleveland, Ohio, United States - (and 5 more...)
|
|
| 11 |
NCT01559727 |
Completed |
Dose-comparison Study of Prednisone in Heart Failure |
|
|
Interventional
|
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Daily urinary volumes
- Urinary sodium excretion
- The effect of prednisone on renin angiotensin aldosterone system.
|
40 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01559727 |
GL-2011-29 |
|
March 2012 |
January 2013 |
March 2013 |
March 21, 2012 |
August 28, 2013 |
|
- The First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China - The First Hospital of Hebei Medical University
Shijiazhuang, China
|
|
| 12 |
NCT00294658 |
Completed
Has Results |
Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy |
|
- Procedure: thymectomy plus prednisone
- Drug: prednisone alone
|
Interventional
|
Phase 3 |
- University of Alabama at Birmingham
- National Institute of Neurological Disorders and Stroke (NINDS)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time-weighted Average Quantitative Myasthenia Gravis Weakness Score Over 3 Years
- Time-weighted Average Alternate-day Prednisone Dose (mg) Measured Over 3 Years
- Subgroup Analyses of Time-weighted Average Quantitative Myasthenia Gravis Score by Prednisone Use at Enrollment
- (and 25 more...)
|
126 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00294658 |
R01NS050733
1U01NS042685-01A2
CRC |
|
June 2006 |
November 2015 |
December 2015 |
February 22, 2006 |
May 23, 2017 |
January 16, 2017 |
- University of Alabama at Birmingham, Department of Neurology, Sparks Center, Suite 350, 1720 7th Avenue South
Birmingham, Alabama, United States - Data Coordination Center: University of Alabama at Birmingham
Birmingham, Alabama, United States - Barrow Neurological Institute, Saint Joseph's Hospital and Medical Center, 350 W Thomas Rd
Phoenix, Arizona, United States - (and 67 more...)
|
|
| 13 |
NCT02302495 |
Active, not recruiting |
Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma |
|
|
Interventional
|
Phase 2 |
- University Hospital, Lille
- Amgen
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose Maximum Tolerate of Carfilzomib Weekly
- number of patients who reach Very Good Partial Response and Complete
|
80 |
All |
65 Years and older (Older Adult) |
NCT02302495 |
2012_32
2012-004490-10 |
IFM2012-03 |
January 2014 |
January 2019 |
July 2021 |
November 27, 2014 |
February 19, 2018 |
|
- Centre Hospitalier H. Duffaut
Avignon, France - Centre Hospitalier de la côte basque
Bayonne, France - Hôpital Jean Minjoz
Besançon, France - (and 30 more...)
|
|
| 14 |
NCT01758120 |
Active, not recruiting |
Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy |
|
- Drug: prednisone plus cyclophosphamide
- Drug: Prednisone alone
|
Interventional
|
Phase 4 |
- Guangdong General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- the changes of kidney function or death
- the changes of proteinuria
|
135 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01758120 |
GGH2012-36 |
TOPplus-IgAN |
December 2012 |
December 2019 |
December 2019 |
January 1, 2013 |
July 14, 2017 |
|
- Guangdong General Hospital
Guangzhou, Guangdong, China
|
|
| 15 |
NCT01809444 |
Unknown † |
Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy |
- Thyroid Associated Opthalmopathies
|
- Drug: Prednisone+placebo of Doxycycline
- Drug: Doxycycline+placebo of Prednisone
|
Interventional
|
Phase 2
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Overall treatment response
- • Health related quality of life questionnaires (GO-QoL)
- • Safety and tolerability as assessed by adverse events, vital signs
- (and 2 more...)
|
146 |
All |
18 Years to 60 Years (Adult) |
NCT01809444 |
5010-doxy |
|
November 2012 |
January 2016 |
January 2016 |
March 12, 2013 |
December 10, 2013 |
|
- Peking Union Medical College Hospital
Beijing, Beijing, China - Zhongshan Ophthalmic Center
Guangzhou, Guangdong, China - JOINT SHANTOU INTERNATIONALL EYE CENTER of Shantou University and the Chinese University of Hong Kong
Shantou, Guangdong, China - (and 3 more...)
|
|
| 16 |
NCT03290456 |
Not yet recruiting |
Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis. |
- Granulomatosis With Polyangitis
|
- Drug: Prednisone 5mg/day extended of 9 additional months
- Drug: Placebo 5mg/day extended of 9 additionnal months.
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Relapse-free survival, relapse being defined as BVAS > 0.
- Compare the rate of serious adverse events between Inclusion and Month 24 after randomization
- Compare the rate of predefined severe events related to glucocorticoids between inclusion and Month 24 including osteoporotic fracture and weight gain.
- (and 9 more...)
|
146 |
All |
18 Years and older (Adult, Older Adult) |
NCT03290456 |
69HCL17_0020 |
MAINEPSAN |
December 1, 2017 |
December 1, 2017 |
December 1, 2021 |
September 25, 2017 |
October 16, 2017 |
|
- Centre Hospitalier Lyon Sud
Pierre-Bénite, France
|
|
| 17 |
NCT03218852 |
Active, not recruiting |
Extended Follow-up of Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy |
|
- Drug: prednisone and cyclophosphamide
- Drug: prednisone alone
|
Interventional
|
Phase 4 |
- Guangdong General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- the changes of kidney function or death
- the changes of proteinuria
- Number of Participants with Adverse Events
|
133 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03218852 |
GGH2012-36-1 |
e-TOPplus |
December 2016 |
December 2021 |
December 2021 |
July 17, 2017 |
July 17, 2017 |
|
- Guangdong General Hospital
Guangzhou, Guangdong, China
|
|
| 18 |
NCT01452100 |
Terminated |
Efficacy of Prednisone in Patients With Severe Systemic Atheroembolism (Cholesterol Cristal Embolism) |
- Cholesterol Embolism Systemic
|
- Drug: prednisone
- Other: placebo
|
Interventional
|
Phase 2 |
- University Hospital, Toulouse
- Ministry of Health, France
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- 1-year survival and 1-year renal survival (composite criteria)
- Number and duration of hospitalization(s)
- course of renal function
- (and 2 more...)
|
39 |
All |
18 Years and older (Adult, Older Adult) |
NCT01452100 |
1003701
2010-021467-33 |
MECCORT |
June 2011 |
September 2015 |
December 2015 |
October 14, 2011 |
May 9, 2016 |
|
- CHU Toulouse service néphrologie
Toulouse, France
|
|
| 19 |
NCT02670707 |
Recruiting |
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH) |
- Langerhans Cell Histiocytosis
|
- Drug: Cytarabine
- Drug: Vinblastine/prednisone
|
Interventional
|
Phase 3 |
- Baylor College of Medicine
- Texas Children's Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time to determine 1-year event-free survival (EFS) of patients treated with cytarabine monotherapy for LCH, compared directly with that of standard-of-care vinblastine/prednisone (Events include progression of LCH, relapse, or death).
- Durable responses with 2-year and 5-year EFS and OS of the patients treated with cytarabine versus vinblastine/prednisone for LCH.
- Number of toxicities (including psychosis, hypertension, neuropathy, fever, headache) in the patients treated with cytarabine versus vinblastine/prednisone for LCH.
- (and 5 more...)
|
124 |
All |
up to 21 Years (Child, Adult) |
NCT02670707 |
H-37718 TXCH LCH0115 |
|
March 7, 2016 |
January 2021 |
January 2025 |
February 2, 2016 |
December 24, 2018 |
|
- Texas Children's Hospital
Houston, Texas, United States
|
|
| 20 |
NCT02367118 |
Unknown † |
Prednisone in Chronic Rhinosinusitis Without Nasal Polyps |
- Sinusitis
- Chronic Rhinosinusitis
|
- Drug: Prednisone
- Drug: Placebo
|
Interventional
|
Phase 3 |
- University of Chile
- Sociedad Chilena de Otorrinolaringología, Medicina y Cirugía de Cabeza y Cuello
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Changes in Symptoms as measured by SNOT 22 questionnaire and visual analogue scale at 6 months
- Change in Olfactory function as measured by "Sniffin'Sticks 12 tests" at 6 months
- Change in Nasal patency as measured by Acoustic rhinometry and Rhinomanometry at 6 months
- Changes in Nasal endoscopy findings as measured by Lund-Kennedy score at 6 months
|
90 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02367118 |
PRD- CRSsNP-1 |
|
June 2015 |
March 2016 |
December 2016 |
February 20, 2015 |
June 4, 2015 |
|
- Hospital del Salvador
Santiago, Region Metropolitana, Chile
|
|
| 21 |
NCT02282683 |
Unknown † |
Long-term Prednisone Use for End-stage Heart Failure |
- Heart Failure
- Hyperuricemia
|
|
Interventional
|
Phase 2
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Mortality within 12 months
- Event-free survival time (defined as time to first hospitalization due to heart failure deterioration or death) within 12 months
- Survival time (defined as time to death) within 12 months
- (and 2 more...)
|
90 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02282683 |
hebmu 201312 |
|
December 2013 |
December 2017 |
December 2017 |
November 4, 2014 |
January 12, 2017 |
|
- The First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
|
|
| 22 |
NCT01133275 |
Active, not recruiting
Has Results |
Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS |
- Myelodysplastic Syndrome
- MDS
|
- Drug: Prednisone
- Drug: Lenalidomide
|
Interventional
|
Phase 2 |
- H. Lee Moffitt Cancer Center and Research Institute
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Erythroid Response
- Number of Participants With Grade 3 or 4 Adverse Events Possibly Related to Treatment
|
28 |
All |
18 Years and older (Adult, Older Adult) |
NCT01133275 |
MCC-16099
RV-MDS-PI-0456
25005/1 |
|
April 28, 2010 |
January 31, 2015 |
June 2019 |
May 28, 2010 |
November 7, 2018 |
January 18, 2016 |
- University of Florida Shands Cancer Center
Gainesville, Florida, United States - H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
|
|
| 23 |
NCT01671423 |
Completed |
Use of a Single Dose of Oral Prednisone in the Treatment of Cellulitis |
|
- Drug: Prednisone
- Drug: Placebo
|
Interventional
|
Not Applicable |
- Albert Einstein Healthcare Network
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Change in VAS for pain - day 1 to 48 hours
- Amount of pain medication - day 1 to 48 hours
- Amount of pain medication - day 1 to 7 days
- (and 5 more...)
|
42 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01671423 |
HN 4372 |
|
August 2012 |
September 2015 |
September 2015 |
August 23, 2012 |
May 8, 2017 |
|
- Albert Einstein Medical Center
Philadelphia, Pennsylvania, United States
|
|
| 24 |
NCT03466801 |
Not yet recruiting |
The Efficacy of Prednisone and Combination Therapy With Methylprednisolone and Cyclophosphamide on IMN in Stage I. |
- Idiopathic Membranous Nephropathy
|
- Drug: Prednisone
- Drug: MP and CTX
|
Interventional
|
Not Applicable |
- Wenhu Liu
- Beijing Friendship Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- nephrotic syndrome remission ( including complete remission and partial remission)
- blood albumin≥30g/L
|
166 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03466801 |
2017-P2-172-02 |
|
March 20, 2018 |
January 30, 2019 |
June 30, 2019 |
March 15, 2018 |
March 15, 2018 |
|
|
|
| 25 |
NCT01837433 |
Completed |
Short-term Prednisone to Treat STA Study(SPTSS) |
|
- Drug: Prednisone 1 week
- Drug: Prednisone 6 weeks
|
Interventional
|
Phase 4 |
- Xinqiao Hospital of Chongqing
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- The Efficiency of experimental group comparing with control group during 14 days
- recurrence rate
- hypothyroidism
- (and 5 more...)
|
40 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01837433 |
XinqiaoH-001 |
STA |
March 2013 |
December 2014 |
December 2014 |
April 23, 2013 |
May 20, 2015 |
|
- The Second Affiliated Hospital, Third Military Medical University
Chongqing, Chongqing, China
|
|
| 26 |
NCT00686335 |
Completed
Has Results |
A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients With Nocturnal Asthma |
|
- Drug: Lodotra
- Drug: Cortancyl
|
Interventional
|
Phase 2 |
- Horizon Pharma Ireland, Ltd., Dublin Ireland
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Total Number of Nocturnal Awakenings During the Last 2 Weeks of Treatment
|
12 |
All |
18 Years and older (Adult, Older Adult) |
NCT00686335 |
NP01-201
EudraCT-Number: 2007-007316-29 |
MONA |
June 2008 |
March 2010 |
May 2010 |
May 29, 2008 |
December 28, 2012 |
December 28, 2012 |
- Hôpital Bichat
Paris, France
|
|
| 27 |
NCT03833921 |
Not yet recruiting
New |
Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer |
- Prostate Cancer Metastatic
- Prostate Cancer
|
- Drug: Abiraterone Acetate
- Drug: Prednisone
|
Interventional
|
Phase 2 |
- Martha Mims
- Baylor College of Medicine
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- PSA Response Rate
- Depth of PSA Response
- Frequency of Potentially Deleterious Polymorphisms
- (and 4 more...)
|
130 |
Male |
18 Years and older (Adult, Older Adult) |
NCT03833921 |
H-44335 |
APRE |
April 2019 |
November 2024 |
April 2034 |
February 7, 2019 |
February 7, 2019 |
|
- Ben Taub General Hospital
Houston, Texas, United States - Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine
Houston, Texas, United States
|
|
| 28 |
NCT01002703 |
Unknown † |
Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma |
|
- Drug: Lenalidomide, Bendamustine, Prednisone
|
Interventional
|
Phase 1
Phase 2 |
- University of Leipzig
- Celgene Corporation
- Mundipharma Pte Ltd.
- Amgen
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the maximum tolerable dose (MTD) of lenalidomide in combination with bendamustine and prednisone (RBP) in refractory and relapsed MM stage I/III
- To determine the safety of lenalidomide, bendamustine and prednisone at MTD
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT01002703 |
RBP-01/08
OSHO77 |
|
September 2009 |
October 2012 |
October 2014 |
October 27, 2009 |
August 12, 2011 |
|
- University of Leipzig
Leipzig, Germany
|
|
| 29 |
NCT00987116 |
Completed |
Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis |
|
- Drug: Prednisone - Azathioprine
|
Interventional
|
Phase 4 |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Proportion of patients who have reach minimal manifestation state (according to MGFA criteria) and are not treated with prednisone after 12 months of treatment and have not relapsed during the next 3 months.
- Cumulative dose of prednisone at twelve months
- Proportion of patients having reached minimal manifestation state 12 months
- (and 5 more...)
|
118 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT00987116 |
P051055 |
MYACOR |
June 2009 |
July 2017 |
September 2017 |
September 30, 2009 |
October 13, 2017 |
|
- Hopital Raymond Poincaré
Garches, France
|
|
| 30 |
NCT01193049 |
Completed
Has Results |
A Study on the Effects of a Single Dose of Prednisone on Biomarkers of Allergen Responses in Asthmatics (MK-0000-175) |
|
- Drug: Prednisone
- Drug: Placebo
|
Interventional
|
Phase 1 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Geometric Mean Fold Change From Baseline in Interleukin-5 (IL-5) Concentration From Nasal Exudates and Sputum at 7 Hours Post-allergen Challenge
- Geometric Mean Fold Change From Baseline in Interleukin-13 (IL-13) From Nasal Exudates and Sputum at 7 Hours Post-allergen Challenge
- Geometric Mean Fold Change From Baseline in Thymus and Activation Regulated Chemokine (TARC) From Nasal Exudates and Sputum at 7 Hours Post-allergen Challenge
- (and 10 more...)
|
11 |
All |
18 Years to 55 Years (Adult) |
NCT01193049 |
0000-175
2010-020518-27 |
|
August 2010 |
May 2011 |
May 2011 |
September 1, 2010 |
September 4, 2015 |
August 2, 2012 |
|
|
| 31 |
NCT01978665 |
Unknown † |
The Effect of Prednisone and Solu-Medrol on Physical Exercise in COPD Patients and Inflammatory Response During and After Exercise |
- Exercise Performance in Copd Patients
|
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
|
- effect on muscle power
- the inflammatory response
|
14 |
Male |
40 Years to 75 Years (Adult, Older Adult) |
NCT01978665 |
2012-004503-13 |
COPDprednisone |
April 2013 |
December 2013 |
December 2013 |
November 7, 2013 |
November 7, 2013 |
|
- Bispebjerg Hospital
Copenhagen, NV, Denmark
|
|
| 32 |
NCT02252237 |
Active, not recruiting |
Pharmacokinetics of Prednisone, Prednisolone, Methylprednisolone in Children |
- Children Receiving Prednisone or Prednisolone or Methylprednisolone
|
- Biological: Pharmacokinetic
|
Observational
|
|
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Composite of Pharmacokinetic parameter for Prednisone, Prednisolone, Methylprednisolone
- Side effects
- Analysis of genetic polymorphism of proteins taking part in glucocorticoids metabolism
|
146 |
All |
Child, Adult, Older Adult |
NCT02252237 |
2014-A00987-40 |
GLUCOPED |
December 3, 2014 |
December 2018 |
June 2019 |
September 30, 2014 |
April 17, 2018 |
|
- AP-HP Necker
Paris, France
|
|
| 33 |
NCT03133897 |
Recruiting |
Dexamethasone Versus Prednisone for Asthma Treatment in the Pediatric Inpatient Population; a Feasibility Study |
|
- Drug: Dexamethasone
- Drug: Prednisone
|
Interventional
|
Phase 3 |
- Children's Hospital of Eastern Ontario
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Other
|
- Health Utilization
- Allocation success
- recruitment success
- (and 2 more...)
|
51 |
All |
18 Months to 17 Years (Child) |
NCT03133897 |
CHEO |
|
March 5, 2018 |
November 2019 |
March 2020 |
April 28, 2017 |
January 14, 2019 |
|
- Children's Hospital of Eastern Ontario
Ottawa, Ontario, Canada
|
|
| 34 |
NCT01260623 |
Completed |
Pilot Study of How Children With Asthma Exacerbations Metabolize Prednisone |
|
- Drug: Prednisolone and prednisone
|
Observational
|
|
- Lawson Health Research Institute
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- pharmacokinetic profile of prednisone and prednisolone
|
20 |
All |
2 Years to 16 Years (Child) |
NCT01260623 |
R-09-406
16380 |
|
September 9, 2009 |
May 31, 2013 |
May 31, 2013 |
December 15, 2010 |
August 28, 2017 |
|
- Pediatric Emergency Department, Children's Hospital, London Health Sciences Centre
London, Ontario, Canada
|
|
| 35 |
NCT00667615 |
Completed
Has Results |
Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) |
- Hodgkin's Disease
- Lymphoma
|
- Drug: rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim
|
Interventional
|
Phase 1
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- Merck Sharp & Dohme Corp.
- Northwestern University
- (and 2 more...)
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of Vorinostat Given Orally for 10 Days in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma
- Complete Response Rate to Rituximab and a Combination of Vorinostat With Cyclophosphamide, Etoposide, and Prednisone in Elderly Pts With Relapsed Diffuse Large B-cell Lymphoma Who Aren't Candidates for Autologous Stem Cell Transplantation.
|
30 |
All |
60 Years and older (Adult, Older Adult) |
NCT00667615 |
08-045 |
|
April 2008 |
February 2017 |
February 2017 |
April 28, 2008 |
January 5, 2018 |
November 7, 2017 |
- Memorial Sloan Kettering Cancer Center @ BaskingRidge
Basking Ridge, New Jersey, United States - Memorial Sloan Kettering Cancer Center @ Suffolk
Commack, New York, United States - Memorial Sloan Kettering Cancer Center
New York, New York, United States - (and 2 more...)
|
|
| 36 |
NCT01711827 |
Completed |
A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Prednisone in Healthy Adult Subjects |
- Healthy Subjects
- Pharmacokinetics of Isavuconazole
- Pharmacokinetics of Prednisolone
|
- Drug: Isavuconazole
- Drug: Prednisone
|
Interventional
|
Phase 1 |
- Astellas Pharma Global Development, Inc.
- Basilea Pharmaceutica International Ltd
- Astellas Pharma Inc
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- Pharmacokinetics of plasma prednisolone: AUClast,
- Pharmacokinetics of plasma prednisolone: AUCinf
- Pharmacokinetics of plasma prednisolone: Cmax
- (and 5 more...)
|
21 |
All |
18 Years to 55 Years (Adult) |
NCT01711827 |
9766-CL-0024 |
|
February 2012 |
March 2012 |
March 2012 |
October 22, 2012 |
October 22, 2012 |
|
- Parexel International, LLC
Glendale, California, United States
|
|
| 37 |
NCT03367663 |
Not yet recruiting |
The Effect of Prednisone on Atherogenesis as Studied in the Macrophage Foam Cell Formation Model System. |
- Atherosclerosis
- Dyslipidemias
- Diabetes
|
- Drug: Prednisone 20 Mg
- Drug: Prednisone 40 Mg
|
Interventional
|
Early Phase 1 |
- Prof. Tony hayek MD
- Rambam Health Care Campus
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
|
20 |
Male |
18 Years to 50 Years (Adult) |
NCT03367663 |
0254-17-RMB |
|
December 2017 |
June 2018 |
December 2018 |
December 11, 2017 |
December 11, 2017 |
|
|
|
| 38 |
NCT03505762 |
Recruiting |
Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment |
- B-Cell Non-Hodgkin Lymphoma
|
- Drug: Cyclophosphamide
- Drug: Doxorubicin Hydrochloride
- Other: Laboratory Biomarker Analysis
- (and 5 more...)
|
Interventional
|
Phase 2 |
- Wake Forest University Health Sciences
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Cumulative incidence of hyperglycemia of standard or tailored rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone (R-CHOP)
- Cumulative incidence of hyperglycemia of standard or tailored R-CHOP
- Response rates of standard or tailored R-CHOP as measured by Cheson's criteria
- (and 3 more...)
|
80 |
All |
18 Years and older (Adult, Older Adult) |
NCT03505762 |
IRB00050108
NCI-2018-00585
CCCWFU 98317
P30CA012197 |
|
July 19, 2018 |
June 2022 |
June 2024 |
April 23, 2018 |
July 27, 2018 |
|
- Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
|
|
| 39 |
NCT03356912 |
Enrolling by invitation |
CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy |
- Prostate Cancer
- Castration-resistant Prostate Cancer
|
- Drug: Cabazitaxel
- Drug: Prednisone
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- change from Baseline radiographic progression
- Health-Related Quality of Life and pain
- Adverse events
- (and 2 more...)
|
220 |
Male |
18 Years and older (Adult, Older Adult) |
NCT03356912 |
CABACARE |
|
November 22, 2017 |
May 4, 2021 |
May 4, 2021 |
November 29, 2017 |
December 14, 2017 |
|
- University Federico II of Naples
Naples, Italy
|
|
| 40 |
NCT03414034 |
Recruiting |
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer |
- Metastatic Castration-Resistant Prostate Cancer
|
- Drug: Onvansertib
- Drug: Abiraterone
- Drug: Prednisone
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With Lack of Prostate-specific Antigen (PSA) Progression per Prostate Cancer Working Group 3 (PCWG3) criteria After 12 Weeks
- Percentage Change from Baseline in PSA at 12 Weeks
- Maximal Percentage Change from Baseline in PSA
- (and 6 more...)
|
25 |
Male |
18 Years and older (Adult, Older Adult) |
NCT03414034 |
TROV-053
U1111-1208-1579 |
|
June 18, 2018 |
May 14, 2019 |
June 11, 2019 |
January 29, 2018 |
January 8, 2019 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States - Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 41 |
NCT03098823 |
Active, not recruiting |
A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE |
- Lupus Erythematosus, Systemic
- Lupus Erythematosus
- Fatigue
|
- Drug: RAYOS
- Drug: Prednisone
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
|
62 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT03098823 |
AMP-002 |
RIFLE |
September 12, 2017 |
April 2019 |
July 2019 |
April 4, 2017 |
December 3, 2018 |
|
- Cedars-Sinai Medical Center
Los Angeles, California, United States - The Regents of the University of California, Los Angeles
Los Angeles, California, United States - University of California-Irvine
Orange, California, United States - (and 18 more...)
|
|
| 42 |
NCT01169597 |
Completed |
Short Term Efficacy of a Starting Dose of 12.5 mg of Prednisone in Polymyalgia Rheumatica Patients |
|
|
Interventional
|
Phase 4 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- clinical remission within one month from the treatment initiation
- to evaluate demographic features as possible predictive factors of response to 12.5 mg of prednisone
- to evaluate characteristics of PMR as predictive factors of response to 12.5 mg of prednisone
- (and 3 more...)
|
60 |
All |
50 Years and older (Adult, Older Adult) |
NCT01169597 |
PMR-PDN001 |
|
January 2009 |
January 2010 |
May 2010 |
July 26, 2010 |
July 26, 2010 |
|
- Clinica Reumatologica, Dipartimento di medicina Interna, Università di Genova
Genova, Italy
|
|
| 43 |
NCT00956059 |
Unknown † |
Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis |
- Focal Segmental Glomerulosclerosis
|
- Drug: prednisone, FK506, MMF
- Drug: prednisone
|
Interventional
|
Not Applicable |
- Health Science Center of Xi’an Jiaotong University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- proteinuria,serum protein,Scr,blood routine examination,liver function test,blood glucose and lipid test
|
40 |
All |
16 Years to 70 Years (Child, Adult, Older Adult) |
NCT00956059 |
CSX-090630-SAHXJTU
DBDZL-1
DX-FSGS-1
YW-JS-XX-TKMS
JL-5MG-50MG-500MG
JG-YX-1 |
|
September 2009 |
December 2012 |
December 2012 |
August 11, 2009 |
August 11, 2009 |
|
- The second affiliated hospital of medical college, Xi'an Jiaotong University
Xi'an, Shaanxi, China
|
|
| 44 |
NCT01424930 |
Completed
Has Results |
A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer |
- Prostate Neoplasms
- Prostate Cancer
|
- Drug: Abiraterone
- Drug: Prednisone
|
Interventional
|
Phase 2 |
- Janssen-Ortho Inc., Canada
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Grade 3 or Higher Adverse Events (AEs) of Special Interest or Grade 3 or Higher Serious AEs Due to Study Medication
- Maximum Observed Plasma Concentration (Cmax) of Abiraterone
- Time to Reach Maximum Observed Plasma Concentration (Tmax) of Abiraterone
- Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h)
|
25 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01424930 |
CR018715
212082PCR2008 |
|
October 2011 |
April 2013 |
May 2013 |
August 29, 2011 |
July 25, 2014 |
April 30, 2014 |
- Edmonton, Alberta, Canada
- Vancouver, British Columbia, Canada
|
|
| 45 |
NCT01066598 |
Terminated |
A Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease (cGVHD) |
- Graft Versus Host Disease
|
|
Interventional
|
Phase 2 |
- University Health Network, Toronto
- Hoffmann-La Roche
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The efficacy of the combination of rituximab and prednisone as initial therapy for C-GVHD, which is defined as discontinuation of immunosuppressive therapy at 12 months with resolution of reversible manifestations of C-GVHD
- To determine the response rate to treatment, defined as complete response plus partial response (PR) for rituximab and prednisone
- To determine the rate of recurrent C-GVHD following initial therapy with rituximab and prednisone
- (and 3 more...)
|
1 |
All |
18 Years and older (Adult, Older Adult) |
NCT01066598 |
OZM-009 (GVHD-R01) |
|
May 2010 |
August 2011 |
August 2011 |
February 10, 2010 |
September 7, 2011 |
|
- Alberta Health Sciences - Tom Baker Cancer Centre
Calgary, Alberta, Canada - Vancouver General Hospital
Vancouver, British Columbia, Canada - Princess Maragaret Hospital
Toronto, Ontario, Canada
|
|
| 46 |
NCT03595917 |
Recruiting |
ABL001 + Dasatinib + Prednisone in BCR-ABL+ B-ALL or CML |
- B-cell Acute Lymphoblastic Leukemia
- Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis
- Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL
|
- Drug: ABL001
- Drug: Dasatinib
- Drug: Prednisone
|
Interventional
|
Phase 1 |
- Marlise R. Luskin
- Novartis
- Dana-Farber Cancer Institute
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD) of ABL001
- Percentage for Participants Achieving Hematologic Remission
- Percentage of participants achieving cytogenetic response
- (and 2 more...)
|
34 |
All |
18 Years and older (Adult, Older Adult) |
NCT03595917 |
18-170 |
|
July 24, 2018 |
November 1, 2019 |
November 1, 2024 |
July 23, 2018 |
October 16, 2018 |
|
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 47 |
NCT03070522 |
Recruiting |
Prednisone in Cystic Fibrosis Pulmonary Exacerbations |
- Cystic Fibrosis Pulmonary Exacerbation
|
- Drug: Prednisone
- Drug: Placebos
|
Interventional
|
Phase 3 |
- The Hospital for Sick Children
- Canadian Cystic Fibrosis Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Lung function recovery
- lung function recovery at follow up visit
- change in pulmonary function testing
- (and 8 more...)
|
84 |
All |
Child, Adult, Older Adult |
NCT03070522 |
REB1000053825 |
PIPE |
May 1, 2017 |
May 2020 |
May 2021 |
March 3, 2017 |
April 17, 2018 |
|
- SickKids
Toronto, Ontario, Canada
|
|
| 48 |
NCT01591122 |
Completed |
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer |
|
- Drug: Placebo and prednisone
- Drug: Abiraterone acetate and prednisone
|
Interventional
|
Phase 3 |
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time to prostate specific antigen (PSA) progression (TTPP)
- Overall survival
- Time to initiation of cytotoxic chemotherapy
- (and 6 more...)
|
313 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01591122 |
CR100011
ABI-PRO-3002 |
|
March 27, 2012 |
December 31, 2016 |
January 31, 2019 |
May 3, 2012 |
February 19, 2019 |
|
- Beijing, China
- Chengdu, China
- Chongqing, China
- (and 21 more...)
|
|
| 49 |
NCT00995722 |
Terminated
Has Results |
Efficacy of Prednisone In the Treatment of Ocular Myasthenia |
|
- Drug: Prednisone
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Michael Benatar
- University of Miami
- University of Rochester
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Treatment Failure
- Change in Ocular Quantitative Myasthenia Score From Baseline to Week 16
- Change in Quality of Life as Measured by the NEI-VFQ-25 Measures
- (and 2 more...)
|
11 |
All |
18 Years and older (Adult, Older Adult) |
NCT00995722 |
FD-R-03710-01 |
EPITOME' |
December 2011 |
October 2013 |
October 2013 |
October 15, 2009 |
June 2, 2017 |
November 2, 2015 |
- Yale University
New Haven, Connecticut, United States - University of Miami
Miami, Florida, United States - University of Kansas Medical Center
Kansas City, Kansas, United States - (and 7 more...)
|
|
| 50 |
NCT00110669 |
Completed |
High-dose Prednisone in Duchenne Muscular Dystrophy |
- Duchenne Muscular Dystrophy
|
|
Interventional
|
Phase 3 |
- Cooperative International Neuromuscular Research Group
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Quantitative muscle strength will be measured using the CINRG Quantitative Measurement System (CQMS)
- Primary strength endpoints will be quantitative myometry (QMT) scores of the upper and lower extremities, consisting of paired flexor/extensor groups.
- Secondary strength endpoints will include individual QMT scores of elbow and knee flexors and extensors and hand grip, manual muscle testing scores, which will be measured using the Medical Research Council's (MRC) muscle strength scoring method.
- Side-effect profiles will assessed by monitoring side-effects, including differences in growth (height and weight), calculated weight/height ratio, bone density, cataract formation, blood glucose, blood pressure and behavioral changes.
|
64 |
Male |
4 Years to 10 Years (Child) |
NCT00110669 |
CNMC0601 |
|
January 2004 |
December 2007 |
February 2008 |
May 13, 2005 |
October 27, 2011 |
|
- Children's National Medical Center
Washington, District of Columbia, United States
|
|
| 51 |
NCT00746512 |
Completed
Has Results |
A Study of the Effects of Oral Prednisone in Patients With Rheumatoid Arthritis (MK0000-088) |
|
- Drug: Prednisone 15 mg
- Drug: Placebo Tablets
- Drug: Prednisone 7.5 mg
- Drug: Placebo Over-Encapsulated Tablets
|
Interventional
|
Phase 1 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Synovial Blood Flow
- Disease Activity Score 28 (DAS28) (C-reactive Protein [CRP])
|
45 |
All |
18 Years and older (Adult, Older Adult) |
NCT00746512 |
0000-088
2008_531 |
|
September 2008 |
September 2009 |
September 2009 |
September 4, 2008 |
May 29, 2015 |
April 8, 2011 |
|
|
| 52 |
NCT00440219 |
Completed |
The Effect of Preoperative Oral Prednisone on the Operative Field During Nasal Polypectomy. |
|
- Drug: Oral Prednisone
- Drug: Placebo comparator
|
Interventional
|
Phase 3 |
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Intraoperative blood loss. Wormald Surgical Field Grading Scale
- Visibility and easy of surgery
- Endoscopic assessment
- Quality of life survey (SNOT22)
|
34 |
All |
18 Years and older (Adult, Older Adult) |
NCT00440219 |
07-0001-A |
|
November 2010 |
December 2012 |
June 2013 |
February 26, 2007 |
January 10, 2014 |
|
- Mount Sinai Hospital, University of Toronto
Toronto, Ontario, Canada - St. Joseph's Health Centre
Toronto, Ontario, Canada
|
|
| 53 |
NCT03732586 |
Recruiting |
Effect of Omega 5 Fatty Acid as an Adyuvant Treatment to Prednisone in Patients With Severe Alcoholic Hepatitis |
|
- Dietary Supplement: Omega 5 fatty acid supplement
- Other: PLACEBO
|
Interventional
|
Not Applicable |
- Hospital General Dr. Manuel Gea González
- Universidad Nacional Autonoma de Mexico
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- 30 Day Survival
- Rate of reponse to steroids at day 7
- Malondialdehyde serum levels
- Oxidative Stress molecules serum levels
|
40 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03732586 |
Hospitalgea |
|
September 30, 2018 |
March 30, 2020 |
September 30, 2020 |
November 6, 2018 |
November 6, 2018 |
|
- Laboratorio de Higado, Pancreas y Motilidad Intestinal. UNIVERSIDAD AUTONOMA DE MEXICO
Mexico City, Cuauhtemoc, Mexico - Hospital General Dr. Manuel Gea Gonzalez
Mexico City, Tlalpan, Mexico
|
|
| 54 |
NCT01924286 |
Completed |
Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone |
- Immune Reconstitution Inflammatory Syndrome
- HIV
- Tuberculosis
|
- Drug: Prednisone
- Drug: Placebo
|
Interventional
|
Phase 3 |
- University of Cape Town
- Institute of Tropical Medicine, Belgium
- Imperial College London
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Development of paradoxical TB-IRIS
- Time to IRIS event
- Severity of IRIS events
- (and 17 more...)
|
240 |
All |
18 Years and older (Adult, Older Adult) |
NCT01924286 |
CIDRI_001
SP.2011.41304.074
DOH-27-0813-4336 |
Pred-ART |
August 30, 2013 |
April 2016 |
April 2017 |
August 16, 2013 |
January 19, 2018 |
|
- Site B Khayelitsha HIV/TB clinic
Cape Town, Western Cape, South Africa
|
|
| 55 |
NCT02129764 |
Completed |
Prednisone for Heart Failure Patients With Hyperuricemia |
- Heart Failure, Hyperuricemia
|
- Drug: Prednisone
- Drug: Allopurinol
|
Interventional
|
Phase 2
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change from baseline in serum creatinine levels
- Change from baseline in uric acid levels
- Change from baseline in Cystatin C
- (and 5 more...)
|
205 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02129764 |
PUSH-PATH 2 |
PUSH-PATH-2 |
December 2013 |
February 2018 |
August 31, 2018 |
May 2, 2014 |
October 16, 2018 |
|
- Shijiazhuang, Hebei, China
|
|
| 56 |
NCT01254513 |
Recruiting |
Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients |
|
- Drug: Docetaxel every 3 weeks + Prednisone
- Drug: Docetaxel weekly+ Prednisone
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Feasibility of 2 different protocols of Docetaxel chemotherapy
- Overall Survival
- Geriatric evaluation
- (and 4 more...)
|
144 |
Male |
75 Years and older (Older Adult) |
NCT01254513 |
GERICO10/0910 (GetugP03) |
GERICO10 |
November 2010 |
May 10, 2017 |
October 2018 |
December 6, 2010 |
October 1, 2018 |
|
- Clinique Claude Bernard
Albi, France - CHI Annemasse-Bonneville
Ambilly, France - Centre Paul Papin
Angers, France - (and 28 more...)
|
|
| 57 |
NCT01605227 |
Completed
Has Results |
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100 |
- Prostate Cancer
- Castration Resistant Prostate Cancer
- Pain
- Prostatic Neoplasms
|
- Drug: cabozantinib
- Drug: prednisone
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Overall Survival (OS)
- Bone Scan Response (BSR)
|
1028 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01605227 |
XL184-307
2012-001834-33 |
COMET-1 |
July 2012 |
September 2014 |
March 2015 |
May 24, 2012 |
March 14, 2018 |
March 14, 2018 |
- Birmingham, Alabama, United States
- Anchorage, Alaska, United States
- Phoenix, Arizona, United States
- (and 261 more...)
|
|
| 58 |
NCT02072863 |
Completed |
A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma |
|
- Drug: Oprozomib
- Drug: Melphalan
- Drug: Prednisone
|
Interventional
|
Phase 1
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) - Phase 1b
- Overall Response Rate (ORR) - Phase 2
- Complete Response Rate (CRR) - Phase 2
- (and 4 more...)
|
9 |
All |
18 Years and older (Adult, Older Adult) |
NCT02072863 |
OPZ006
2013-002125-27 |
|
January 2014 |
January 2015 |
September 2015 |
February 27, 2014 |
May 2, 2017 |
|
- Department of Clinical Therapeutics, University of Athens
Athens, Attica, Greece - Ospedale Oncologico Regionale
Rionero in Vulture, Potenza, Italy - Azienda Ospedaliera Universitaria S Martino
Genova, Italy - (and 5 more...)
|
|
| 59 |
NCT01468532 |
Unknown † |
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer |
- Adenocarcinoma of the Prostate
- Hormone-resistant Prostate Cancer
- Recurrent Prostate Cancer
- Stage IV Prostate Cancer
|
- Drug: docetaxel
- Drug: pasireotide
- Drug: prednisone
|
Interventional
|
Phase 1
Phase 2 |
- Barbara Ann Karmanos Cancer Institute
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Occurrence of adverse events and the associated grade per NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 to identify the maximum tolerated dose (MTD) of pasireotide in combination with docetaxel and prednisone
- All specific types of toxicity as assessed via NCI CTCAE version 4.0
- Measurements of tumor using Response Evaluation Criteria In Solid Tumors (RECIST) criteria before and after treatment with the combination of pasireotide in combination with docetaxel
- (and 6 more...)
|
24 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01468532 |
2011-031
NCI-2011-03216 |
|
October 2011 |
March 2017 |
March 2017 |
November 9, 2011 |
December 6, 2016 |
|
- Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
|
|
| 60 |
NCT01411514 |
Terminated |
Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis |
|
- Drug: Prednisone
- Drug: Placebo
|
Interventional
|
Phase 4 |
- Claudio Gobbi
- Ente Ospedaliero Cantonale, Ticino, Switzerland
- Ospedale Civico, Lugano
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Expanded Disability Status Scale (EDSS)
- Multiple Sclerosis Functional Composite Score (MSFC)
- Gd-enhancing lesions on T1-weighted images
- (and 6 more...)
|
27 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT01411514 |
EOC.NC.10.04 |
|
August 2011 |
January 2015 |
January 2015 |
August 8, 2011 |
December 18, 2015 |
|
- Osepdale Civico
Lugano, Ticino, Switzerland
|
|
| 61 |
NCT01785979 |
Withdrawn |
Prednisone Plus Chloroquine for the Treatment of Hyper-reactive Malarial Splenomegaly |
- Hyper-reactive Malarial Splenomegaly
- Malaria
- Anaemia
|
- Drug: prednisone induction - chloroquine
- Drug: Chloroquine
|
Interventional
|
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- composite clinical & immunological endpoint
- 3 months intermediate clinical cure
- 6 months intermediate clinical cure
- (and 3 more...)
|
0 |
All |
18 Years and older (Adult, Older Adult) |
NCT01785979 |
LiHMS |
LiHMS |
January 2016 |
February 2017 |
February 2017 |
February 7, 2013 |
November 13, 2015 |
|
- Lihir medical Centre
Londolovit, New ireland province, Papua New Guinea
|
|
| 62 |
NCT01619813 |
Completed |
Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer |
|
- Drug: Docetaxel, Reolysin and Prednisone
- Drug: Docetaxel and Prednisone
|
Interventional
|
Phase 2 |
- Canadian Cancer Trials Group
- Oncolytics Biotech
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease Progression
- Effect of Docetaxel and Reolysin on circulating tumour cells
- PSA change rate
- (and 4 more...)
|
85 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01619813 |
I209 |
|
July 2012 |
April 2016 |
May 2016 |
June 14, 2012 |
January 23, 2019 |
|
- Tom Baker Cancer Centre
Calgary, Alberta, Canada - Cross Cancer Institute
Edmonton, Alberta, Canada - BCCA - Abbotsford Centre
Abbotsford, British Columbia, Canada - (and 8 more...)
|
|
| 63 |
NCT00815919 |
Completed
Has Results |
Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease |
- Chronic Graft Versus Host Disease
|
- Drug: bortezomib
- Drug: Prednisone
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Millennium Pharmaceuticals, Inc.
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate After a 15 Week Course of Bortezomib Plus Prednisone in Patients With cGVHD
- Proportion of Patients Tolerating >50% Steroid Dose Reduction After a 15 Week Course of Bortezomib Plus Prednisone in Patients With cGVHD
- The Toxicity of a 15 Week Course of Bortezomib Plus Prednisone in Patients With cGVHD
- (and 2 more...)
|
22 |
All |
18 Years and older (Adult, Older Adult) |
NCT00815919 |
08-191 |
|
December 2008 |
January 2012 |
January 2013 |
December 31, 2008 |
July 22, 2015 |
February 28, 2014 |
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 64 |
NCT01594918 |
Completed |
Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer |
- Metastatic Castration-resistant Prostate Cancer
|
- Drug: Cabazitaxel
- Drug: Mitoxantrone
- Drug: Prednisone
- Drug: Pegfilgrastim
|
Interventional
|
Phase 1 |
- Rahul Aggarwal
- Sanofi
- University of California, San Francisco
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determination of the maximum tolerated dose (MTD) of the combination of cabazitaxel and mitoxantrone/prednisone as chemotherapy for patients with metastatic CRPC who have not received prior chemotherapy for metastatic disease.
- Dose Limiting Toxicity (DLT)
- Reduction in Prostate Specific Antigen (PSA), of the combination of cabazitaxel and mitoxantrone/prednisone in patients with metastatic CRPC who have not received prior chemotherapy for metastatic disease.
- Efficacy of drug combination including objective response rate and duration of response
|
25 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01594918 |
UCSF Protocol No. 11951 |
|
June 2012 |
August 2016 |
June 23, 2017 |
May 9, 2012 |
July 21, 2017 |
|
- Mayo Clinic
Scottsdale, Arizona, United States - UCSF Comprehensive Cancer Center
San Francisco, California, United States - Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
|
|
| 65 |
NCT02913196 |
Recruiting |
Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC |
- Prostate Cancer Metastatic
|
- Drug: Apalutamide
- Drug: Abiraterone acetate
- Drug: Docetaxel
- Drug: Prednisone
|
Interventional
|
Phase 1 |
- Weill Medical College of Cornell University
- Janssen Scientific Affairs, LLC
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.
|
24 |
Male |
Child, Adult, Older Adult |
NCT02913196 |
1509016578 |
|
December 2016 |
December 2020 |
March 2021 |
September 23, 2016 |
January 14, 2019 |
|
- GU Research Network/Urology Cancer Center
Omaha, Nebraska, United States - Columbia University Medical Center
New York, New York, United States - Weill Cornell Medical College
New York, New York, United States
|
|
| 66 |
NCT03128905 |
Recruiting |
Trial of Colchicine Versus Prednisone for the Treatment of Acute CPPD Arthritis |
|
- Drug: Colchicine opocalcium 1mg
- Drug: Prednisone : Cortancyl 20mg
|
Interventional
|
Phase 3 |
- Lille Catholic University
- University Hospital, Lille
- Centre Hospitalier Universitaire, Amiens
- (and 4 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change from baseline in the pain VAS at 24 hours
- Proportion of patients with at least one adverse event within 48 hours
- Change from baseline of biological inflammatory syndrome at 48 hours
- (and 8 more...)
|
112 |
All |
65 Years and older (Older Adult) |
NCT03128905 |
RC-P0050 |
COLCHICORT |
February 5, 2018 |
August 5, 2019 |
August 5, 2019 |
April 25, 2017 |
August 22, 2018 |
|
- CH Valenciennes
Valenciennes, Hauts-de-France, France - Hôpital Bichat
Paris, Ile De France, France - CHRU Lille
Lille, Nord Pas De Calais, France - (and 2 more...)
|
|
| 67 |
NCT00146640 |
Completed
Has Results |
Prednisone Timed-Release Tablet (TRT) Study: Modified-Release (MR) Formulation of Prednisone Compared to Standard Immediate-Release (IR) Prednisone in Participants With Rheumatoid Arthritis |
|
- Drug: MR Prednisone
- Drug: IR Prednisone
- Drug: Placebo - MR Prednisone
- Drug: Placebo - IR Prednisone
|
Interventional
|
Phase 3 |
- Merck KGaA, Darmstadt, Germany
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Relative Change From Baseline in Duration of Morning Stiffness at Week 12
- Relative Change From Baseline in 28-Joint Disease Activity Score (DAS28) at Week 12
- Percentage of Participants With Recurrence of Joint Stiffness at Week 12
- (and 5 more...)
|
288 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT00146640 |
EMR 62215-003 |
|
August 31, 2004 |
January 31, 2007 |
January 31, 2007 |
September 7, 2005 |
July 3, 2018 |
May 28, 2018 |
- Research Site
Aachen, Germany - Research Site
Bad Kreuznach, Germany - Research Site
Berlin, Germany - (and 21 more...)
|
|
| 68 |
NCT00414414 |
Withdrawn |
A RCT of Prednisone as Adjunctive Therapy for Hospitalized Patients With Pulmonary TB and HIV Co-infection |
- Tuberculosis
- HIV Infections
|
- Drug: Prednisone
- Drug: placebo
|
Interventional
|
Phase 3 |
- Ottawa Hospital Research Institute
- Ontario Lung Association
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Our primary objective is to determine if 30-day survival will be improved with addition of prednisone to quadruple standard TB therapy. We will measure all cause mortality at 30 days.
- Our secondary endpoints will involve the measurement of clinical, laboratory and radiological parameters and adverse reactions.
|
0 |
All |
17 Years and older (Child, Adult, Older Adult) |
NCT00414414 |
2006301-01H |
|
February 2007 |
June 2009 |
June 2009 |
December 21, 2006 |
April 4, 2017 |
|
- The Ottawa Hospital - General Campus
Ottawa, Ontario, Canada - Erendale Hospital
Pietermaritzburg, KwaZulu Natal, South Africa
|
|
| 69 |
NCT03661684 |
Completed |
Effect of Short Course of Glucocorticoid in Patients With Diabetes Mellitus(DM) Type 2 |
- Diabetes
- Hyperglycemia Steroid-induced
|
|
Interventional
|
Early Phase 1 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- AUC for glucose during OGTT
- HOMA index
- AUC for Insulin during OGTT
|
10 |
All |
18 Years to 50 Years (Adult) |
NCT03661684 |
JHStrogerHEndoSteroid01 |
|
June 3, 2016 |
April 1, 2017 |
July 1, 2017 |
September 7, 2018 |
September 7, 2018 |
|
|
|
| 70 |
NCT02097303 |
Completed
Has Results |
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis |
|
- Drug: Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone
|
Interventional
|
Phase 2 |
- Carolina Research Professionals, LLC
- Bayer
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number and Percentage of Participants With Clinically Meaningful Improvement (Between Baseline and End of Treatment) in Quality-of-Life Determined by the Minimum Increase From Baseline in Scores as Per the QOL CMI Criteria
- Number and Percentage of Participants With Clinically Meaningful Improvement (CMI) in Pain (Between Baseline and End of Treatment)
- Safety Data Was Analyzed and Summarized in Subjects Who Receive at Least One Infusion of Radium Ra 223 Dichloride. Number of Adverse Events Are Being Reported.
- (and 2 more...)
|
36 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02097303 |
CRP-PCA-01 eRADicAte |
eRADicAte |
March 2014 |
December 2015 |
December 2015 |
March 27, 2014 |
February 1, 2018 |
February 1, 2018 |
- Chesapeake urology Research Associates
Towson, Maryland, United States - Urology Cancer Center and GU Research Network
Omaha, Nebraska, United States - Associated Medical Professionals
Syracuse, New York, United States - (and 2 more...)
|
|
| 71 |
NCT00571675 |
Completed |
A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC) |
- Hormone Refractory Prostate Cancer
|
- Drug: AT-101, prednisone and docetaxel
- Drug: placebo, prednisone and docetaxel
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- To evaluate and compare the two treatment arms with respect to overall survival (OS)
- To evaluate and compare progression-free survival (PFS) in men with chemotherapy-naïve metastatic HRPC treated with AT-101 in combination with docetaxel and prednisone versus docetaxel and prednisone plus placebo.
- To determine the toxicities associated with oral AT-101 administered in combination with docetaxel and prednisone.
- To evaluate PSA and objective tumor response rate.
|
220 |
All |
18 Years and older (Adult, Older Adult) |
NCT00571675 |
AT-101-CS-205 |
|
October 2007 |
September 2010 |
September 2010 |
December 12, 2007 |
November 9, 2010 |
|
- Colorado Springs, Colorado, United States
- New Port Richey, Florida, United States
- Ocoee, Florida, United States
- (and 32 more...)
|
|
| 72 |
NCT00350051 |
Completed |
ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer |
|
- Drug: Sagopilone (ZK 219477) + prednisone
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- PSA Response to treatment with ZK-Epo plus prednisone after 6 cycles
- Safety & Tolerability of ZK-Epo plus prednisone
|
53 |
Male |
18 Years and older (Adult, Older Adult) |
NCT00350051 |
91500
307976 |
|
August 2006 |
September 2008 |
December 2009 |
July 10, 2006 |
December 4, 2014 |
|
- Fountain Valley, California, United States
- Sarasota, Florida, United States
- Baltimore, Maryland, United States
- (and 14 more...)
|
|
| 73 |
NCT01578655 |
Completed |
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer |
|
- Drug: cabazitaxel
- Drug: prednisone
- Drug: custirsen sodium
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Survival in the intent-to-treat population
- Survival in the poor-prognosis patient population
- Progression-free survival at Day 140
|
630 |
Male |
Child, Adult, Older Adult |
NCT01578655 |
OGX-011-12 |
AFFINITY |
August 2012 |
July 2016 |
July 2016 |
April 17, 2012 |
October 12, 2016 |
|
- Prostate Oncology Specialists
Marina Del Rey, California, United States - University of California Davis Medical Center
Sacramento, California, United States - Sharp Health Care
San Diego, California, United States - (and 91 more...)
|
|
| 74 |
NCT01241006 |
Completed |
Single Oral Dose of Dexamethasone Versus Five Days of Prednisone in Adult Asthma |
- Asthma
- Reactive Airway Disease
|
- Drug: Dexamethasone
- Drug: Prednisone
|
Interventional
|
Phase 4 |
- Alameda County Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Relapse for worsening asthma within 14 days of ED visit
- Compliance
- Side effects
- Symptoms persistence or improvement
|
376 |
All |
18 Years to 55 Years (Adult) |
NCT01241006 |
IRB10-08103G |
|
January 2011 |
May 2015 |
May 2015 |
November 16, 2010 |
January 7, 2016 |
|
- Alameda County Medical Center
Oakland, California, United States
|
|
| 75 |
NCT02334813 |
Completed
Has Results |
Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia |
- Purpura, Thrombocytopenic, Idiopathic
|
- Drug: Prednisone
- Drug: Dexamethasone
|
Interventional
|
Phase 3 |
- University Hospital, Essen
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
26 |
All |
18 Years and older (Adult, Older Adult) |
NCT02334813 |
EIS2002 |
EIS2002 |
July 2002 |
January 2015 |
January 2015 |
January 8, 2015 |
June 9, 2017 |
June 9, 2017 |
|
|
| 76 |
NCT01848067 |
Completed
Has Results |
Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer |
- Adenocarcinoma of the Prostate
- Hormone-resistant Prostate Cancer
- Recurrent Prostate Cancer
- Stage IV Prostate Cancer
|
- Drug: Alisertib
- Drug: Abiraterone acetate
- Drug: Prednisone
|
Interventional
|
Phase 1
Phase 2 |
- Sidney Kimmel Cancer Center at Thomas Jefferson University
- Millennium: The Takeda Oncology Company
- Thomas Jefferson University
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase I: Frequency of Dose Limiting Toxicities of Alisertib, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.1
- Phase II: Duration of Progression Free Survival According to the PCWG2 Criteria
- Number of Participants With a PSA Value Equal to or Greater Than 25%
|
9 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01848067 |
13P.128
2013-02 |
|
August 14, 2013 |
March 3, 2015 |
June 23, 2016 |
May 7, 2013 |
December 6, 2017 |
December 6, 2017 |
- Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
|
| 77 |
NCT01949337 |
Active, not recruiting |
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer |
- Adenocarcinoma of the Prostate
- Hormone-resistant Prostate Cancer
- Recurrent Prostate Cancer
- Stage IV Prostate Cancer
|
- Drug: enzalutamide
- Drug: abiraterone
- Drug: prednisone
|
Interventional
|
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Astellas Pharma US, Inc.
- (and 2 more...)
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Grade 3 or higher toxicity profile using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
- Decline in Prostate Specific Antigen (PSA)
- (and 4 more...)
|
1311 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01949337 |
A031201
U10CA031946
NCI-2013-01737 |
|
January 2014 |
December 2019 |
|
September 24, 2013 |
April 9, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Southern Cancer Center PC-Providence
Mobile, Alabama, United States - Katmai Oncology Group
Anchorage, Alaska, United States - (and 536 more...)
|
|
| 78 |
NCT00561106 |
Completed |
Prednisone-Placebo vs Prednisone-Valacyclovir in Bell´s Palsy |
|
- Drug: prednisone- valacyclovir
- Drug: prednisone-placebo
|
Interventional
|
Not Applicable |
- Universidad de la Republica
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- The following parameters were used to evaluate the final result: grade of recovery, and sequelae.Facial nerve function was assessed using the facial grading system (FGS) Normal recovery was defined as the return of facial function to FGS 90 or more.
|
42 |
All |
14 Years to 82 Years (Child, Adult, Older Adult) |
NCT00561106 |
HC 6-8-02 |
PVBP |
December 2002 |
|
December 2003 |
November 20, 2007 |
November 20, 2007 |
|
- Hospital de clinicas
Montevideo, Uruguay
|
|
| 79 |
NCT02072200 |
Completed
Has Results |
Efficacy of Lodotra®(Prednisone) in Reduction of Morning Stiffness Duration(K-IMPROvE) |
|
|
Interventional
|
Phase 4 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change From Baseline in Morning Stiffness Duration at Week 12 as Assessed by Patient Diary
- Change of Baseline Severity of Morning Stiffness at Week 12 Using Visual Analog Scale (VAS) Scale
- Change of Functional Disability Index of the Korea Health Assessment Questionnaire (KHAQ) From Baseline to Week 12
|
147 |
All |
20 Years to 80 Years (Adult, Older Adult) |
NCT02072200 |
LOD13-KR-401 |
|
September 2013 |
April 2015 |
April 2015 |
February 26, 2014 |
August 8, 2016 |
August 8, 2016 |
- Hallym University Sacred Heart Hospital
Pyeongchon, Kyungkido, Korea, Republic of
|
|
| 80 |
NCT02685267 |
Active, not recruiting |
Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer |
|
- Drug: Docetaxel
- Drug: Enzalutamide
- Drug: Prednisone
|
Interventional
|
Phase 2 |
- Prostate Cancer Clinical Trials Consortium
- University of Chicago
- Astellas Pharma Inc
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival (radiographic or per PCWG2 criteria)
- PSA response in the standard treatment arm and experimental treatment arm
- Overall survival
|
9 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02685267 |
c13-126 |
Doce/Enza |
February 2016 |
December 2018 |
December 2018 |
February 18, 2016 |
July 16, 2018 |
|
- The University of Chicago
Chicago, Illinois, United States - Decatur Memorial Hospital
Decatur, Illinois, United States - NorthShore University HealthSytem - Kellogg Cancer Center
Evanston, Illinois, United States - (and 2 more...)
|
|
| 81 |
NCT01084655 |
Completed |
Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer |
|
- Drug: TAK-700
- Drug: Docetaxel
- Drug: Prednisone
|
Interventional
|
Phase 1
Phase 2 |
- Millennium Pharmaceuticals, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To confirm the maximum dose of TAK-700 that can be safely administered in combination with docetaxel and prednisone
- To characterize the pharmacokinetics (PK) of docetaxel and TAK-700 alone and in combination
- To obtain an estimate of prostate-specific antigen (PSA) response rates
- (and 3 more...)
|
38 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01084655 |
C21003 |
|
July 2010 |
January 2013 |
February 2013 |
March 10, 2010 |
April 4, 2016 |
|
- Alaska Clinical Research Center, LLC
Anchorage, Alaska, United States
|
|
| 82 |
NCT02184299 |
Completed |
Study of Nevirapine and Prednisone to Determine the Safety and Effectiveness in Preventing Nevirapine Associated Rash in Human Immunodeficiency Virus (HIV) Infected Patients |
|
- Drug: Nevirapine
- Drug: Prednisone
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of rash
- Severity of rash
- Change in Human Immunodeficiency Virus -1 Ribonucleic Acid (HIV-1 RNA) count
- (and 2 more...)
|
138 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02184299 |
1100.1286 |
|
April 1999 |
January 2000 |
|
July 9, 2014 |
July 14, 2014 |
|
|
|
| 83 |
NCT01190787 |
Active, not recruiting |
Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone |
|
- Drug: velcade subcutaneous melphalan prednisone
- Drug: velcade cyclophosphamide prednisone
- Drug: velcade prednisone
|
Interventional
|
Phase 2 |
- Stichting Hemato-Oncologie voor Volwassenen Nederland
- Fondazione Neoplasie Sangue Onlus
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Very Good Partial Response, Complete response rate , Partial response rate
- Progression free survival
- Time to progression
- (and 5 more...)
|
150 |
All |
18 Years and older (Adult, Older Adult) |
NCT01190787 |
26866138MMY2069 |
|
July 2010 |
May 2012 |
May 2020 |
August 30, 2010 |
August 2, 2018 |
|
- Division of Hematology, A.O.U. San Giovanni Battista
Torino, Italy
|
|
| 84 |
NCT02237820 |
Recruiting |
Dexamethasone Versus Prednisone in Heart Failure Patients, Hospitalized With Exacerbation of Chronic Obstructive Pulmonary Disease. |
- Heart Failure
- Chronic Obstructive Pulmonary Disease
|
- Drug: Dexamethasone
- Drug: Prednisone
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Length of hospital stay
- Change from Baseline in body weight at 14 days
- Rate of re-admission
|
80 |
All |
40 Years and older (Adult, Older Adult) |
NCT02237820 |
no specific protocol ID |
|
November 2014 |
January 2020 |
April 2020 |
September 11, 2014 |
January 11, 2019 |
|
- Beilinson Hospital, Rabin Medical Center
Petah Tikva, Israel
|
|
| 85 |
NCT00988208 |
Completed
Has Results |
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer |
|
- Drug: Lenalidomide
- Drug: Docetaxel
- Drug: Prednisone
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Overall Survival (OS)
- Progression-Free Survival (PFS)
- Percentage of Participants With an Objective Response According to Response Evaluation Criteria in Solid Tumors - RECIST Version 1.1 Criteria
- (and 4 more...)
|
1059 |
Male |
18 Years and older (Adult, Older Adult) |
NCT00988208 |
CC-5013-PC-002
EudraCT Number 2008-007969-23 |
Mainsail |
November 11, 2009 |
January 13, 2012 |
November 28, 2016 |
October 2, 2009 |
April 4, 2018 |
September 5, 2013 |
- Hematology Oncology Associates
Phoenix, Arizona, United States - Northern AZ Hematology and Oncology Assoc
Sedona, Arizona, United States - Arizona Oncology
Tucson, Arizona, United States - (and 207 more...)
|
|
| 86 |
NCT02287610 |
Completed
Has Results |
A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid Arthritis |
|
- Drug: RAYOS (delayed-release prednisone)
|
Observational
|
|
- Horizon Pharma Ireland, Ltd., Dublin Ireland
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Mean Change in Severity of Morning Stiffness (Using 100mm VAS) From Baseline (Week 0) to Final Follow-Up Visit
- Change in Duration of Morning Stiffness (Minutes) From Baseline to Final Visit (Final Follow-Up Visit)
- Change in Patient's Overall Assessment in Disease Activity From Baseline to Final Visit (Final Follow-up Visit)
- (and 26 more...)
|
75 |
All |
18 Years and older (Adult, Older Adult) |
NCT02287610 |
HZ-PRE-NIS02 |
SUNRAY |
November 2014 |
October 2015 |
October 2015 |
November 10, 2014 |
February 3, 2017 |
February 3, 2017 |
|
|
| 87 |
NCT00836810 |
Completed
Has Results |
Timed Release Tablet Prednisone in Polymyalgia Rheumatica |
|
- Drug: Timed Release Tablet Prednisone
- Drug: Prednisolone
|
Interventional
|
Phase 2
Phase 3 |
- University Hospitals Bristol NHS Foundation Trust
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Peak Serum IL-6 Concentration
- Change in Area Under the Curve (AUC) of Plasma IL-6
- Percentage Change in Morning Stiffness
- (and 3 more...)
|
12 |
All |
50 Years to 85 Years (Adult, Older Adult) |
NCT00836810 |
ME/2008/3031 |
|
October 2009 |
November 2010 |
March 2011 |
February 4, 2009 |
February 2, 2018 |
February 2, 2018 |
- University Hospitals Bristol NHS Trust
Bristol, Avon, United Kingdom
|
|
| 88 |
NCT00227591 |
Completed
Has Results |
Lenalidomide and Prednisone in Treating Patients With Myelofibrosis |
- Essential Thrombocythemia
- Polycythemia Vera
- Primary Myelofibrosis
|
- Drug: lenalidomide
- Drug: prednisone
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
48 |
All |
18 Years and older (Adult, Older Adult) |
NCT00227591 |
NCI-2012-02976
ECOG-E4903
E4903
U10CA021115 |
|
December 2005 |
December 2010 |
December 2010 |
September 28, 2005 |
May 21, 2014 |
September 26, 2013 |
- Eastern Cooperative Oncology Group
Boston, Massachusetts, United States
|
|
| 89 |
NCT01862965 |
Active, not recruiting |
Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus |
- Chronic Graft-versus-host Disease
|
|
Interventional
|
Phase 2 |
- Universitätsklinikum Hamburg-Eppendorf
- Novartis
- Crolll Gmbh
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- rate of treatment success
- the overall survival rate of patients treated with prednisone and everolimus for chronic GvHDcGvHD
- time to treatment failure
- (and 3 more...)
|
38 |
All |
18 Years and older (Adult, Older Adult) |
NCT01862965 |
PredEver first
2011-004847-35 |
PredEver first |
October 2012 |
February 7, 2018 |
June 2018 |
May 27, 2013 |
April 19, 2018 |
|
- Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany - Universitätsklinikum Jena
Jena, Germany - Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Mainz, Germany - (and 3 more...)
|
|
| 90 |
NCT00644306 |
Terminated |
Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma |
- Newly Diagnosed, Multiple Myeloma
|
- Drug: Thalidomide
- Drug: melphalan, prednisone
- Drug: melphalan, prednisone, thalidomide
|
Interventional
|
Phase 3 |
- Central Hospital, Nancy, France
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- overall Survival
- Progression Free Survival
- Response rates
- Safety
|
232 |
All |
75 Years and older (Older Adult) |
NCT00644306 |
University Hospital, Nancy |
IFM 01/01 |
April 2002 |
|
May 2007 |
March 26, 2008 |
March 26, 2008 |
|
- CHU Nancy - Brabois, rue du morvan
Vandoeuvre, France
|
|
| 91 |
NCT00929695 |
Completed
Has Results |
Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease |
- Graft Versus Host Disease
- Recurrent Adult Acute Lymphoblastic Leukemia
|
- Drug: prednisone
- Drug: methylprednisolone
- Other: questionnaire administration
|
Interventional
|
Phase 3 |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Mean Cumulative Prednisone Dose (mg/kg) Over 42 Days From the Start of Treatment
- Prednisone-associated Toxicity as Assessed by Hyperglycemia
- Prednisone-associated Toxicity as Assessed by Invasive Infections (Bacterial, Fungal and Viral)
- (and 9 more...)
|
164 |
All |
Child, Adult, Older Adult |
NCT00929695 |
2327.00
NCI-2010-00323
P01CA018029 |
|
June 2009 |
July 2013 |
December 14, 2015 |
June 29, 2009 |
August 21, 2017 |
October 9, 2014 |
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
| 92 |
NCT02268149 |
Completed |
Study to Evaluate the Effect of Multiple Doses of BIIL 284 BS on the Pharmacokinetics of Prednisone in Healthy Male Subjects |
|
- Drug: BIIL 284 BS
- Drug: Prednisone
- Drug: Placebo
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- AUC (Area under the concentration-time curve of the analyte in plasma)
- Cmax (Maximum measured concentration of the analyte in plasma)
- tmax (Time from dosing to the maximum concentration of the analyte in plasma)
- (and 8 more...)
|
20 |
Male |
18 Years to 50 Years (Adult) |
NCT02268149 |
543.24 |
|
April 2000 |
July 2000 |
|
October 20, 2014 |
October 20, 2014 |
|
|
|
| 93 |
NCT01017939 |
Completed |
A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer |
|
- Drug: Abiraterone acetate
- Drug: Prednisone
- Drug: Dextromethorphan hydrobromide
- Drug: Theophylline
|
Interventional
|
Phase 1 |
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Ratio of the mean area under the concentration curve (AUC) of dextromethorphan, dextrorphan, and parent/metabolite, with and without co-administration of abiraterone acetate and prednisone
- Ratio of the mean maximum plasma concentration (Cmax) of dextromethorphan, dextrorphan, and parent/metabolite, with and without co-administration of abiraterone acetate and prednisone
- Ratio of the mean area under the concentration curve (AUC) of theophylline with and without co-administration of abiraterone acetate and prednisone
- (and 2 more...)
|
34 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01017939 |
CR017128
COU-AA-015 |
|
January 2010 |
June 2010 |
April 2012 |
November 23, 2009 |
April 12, 2013 |
|
- Tower Cancer Research Foundation
Beverly Hills, California, United States - Beverly Hills, California, United States
- START - South Texas Accelerated Research Therapeutics, LLC
San Antonio, Texas, United States - (and 3 more...)
|
|
| 94 |
NCT00676650 |
Terminated
Has Results |
Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy |
|
- Drug: Prednisone
- Drug: sunitinib
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Overall Survival (OS)
- Progression-Free Survival (PFS)
- Percent of Participants With Objective Response (OR)
- (and 4 more...)
|
873 |
Male |
18 Years and older (Adult, Older Adult) |
NCT00676650 |
A6181120 |
SUN 1120 |
July 2008 |
December 2011 |
December 2011 |
May 13, 2008 |
March 8, 2013 |
March 8, 2013 |
- Pfizer Investigational Site
Decatur, Alabama, United States - Pfizer Investigational Site
Huntsville, Alabama, United States - Pfizer Investigational Site
Huntsville, Alabama, United States - (and 202 more...)
|
|
| 95 |
NCT03748641 |
Not yet recruiting |
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer |
- Metastatic Prostate Cancer
|
- Drug: Niraparib
- Drug: Abiraterone Acetate
- Drug: Prednisone
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Radiographic Progression Free Survival (rPFS)
- Overall survival (OS)
- Time to Chronic Opioid Use
- (and 7 more...)
|
1000 |
Male |
18 Years and older (Adult, Older Adult) |
NCT03748641 |
CR108534
2017-003364-12
64091742PCR3001 |
|
January 14, 2019 |
July 21, 2022 |
February 25, 2025 |
November 21, 2018 |
January 11, 2019 |
|
- Urological Associates of Southern Arizona, P.C.
Tucson, Arizona, United States - Kaiser Permanente Medical Center
Vallejo, California, United States - Advanced Urology Institute
Daytona Beach, Florida, United States - (and 237 more...)
|
|
| 96 |
NCT03750383 |
Completed |
Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects |
|
- Drug: EDP-938
- Drug: Cyclosporine
- Drug: Prednisone
|
Interventional
|
Phase 1 |
- Enanta Pharmaceuticals
- Pharmaceutical Research Associates
|
Industry / Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Cmax of EDP-938 with and without coadministration with cyclosporine
- AUC of EDP-938 with and without coadministration with cyclosporine
- Cmax of EDP-938 with and without coadministration with prednisone
- (and 2 more...)
|
48 |
All |
18 Years to 55 Years (Adult) |
NCT03750383 |
EDP 938-002 |
|
November 2, 2018 |
November 17, 2018 |
December 13, 2018 |
November 22, 2018 |
February 12, 2019 |
|
- Pharmaceutical Research Associates, Inc.,
Lenexa, Kansas, United States
|
|
| 97 |
NCT00919243 |
Completed |
Prednisone for Heart Failure Patients With Hyperuricemia |
- Heart Failure
- Hyperuricemia
|
- Drug: prednisone
- Drug: allopurinol
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change from baseline in uric acid level
- Change from baseline in creatinine clearance rate
- Daily urine volume
- (and 4 more...)
|
40 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT00919243 |
hebmu 08-12 |
|
February 2009 |
July 2010 |
August 2010 |
June 12, 2009 |
September 1, 2010 |
|
- Kunshen Liu
Shijiazhuang, Hebei, China
|
|
| 98 |
NCT02815059 |
Withdrawn |
Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone |
- Acute Lymphoblastic Leukemia
|
- Drug: Ibrutinib
- Drug: Dasatinib
- Drug: Prednisone
|
Interventional
|
Phase 1 |
- University of Utah
- Janssen, LP
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of adverse events of combination of ibrutinib and dasatinib
|
0 |
All |
60 Years and older (Adult, Older Adult) |
NCT02815059 |
HCI85188 |
|
September 28, 2016 |
January 9, 2018 |
January 9, 2018 |
June 28, 2016 |
January 31, 2018 |
|
- Huntsman Cancer Institute
Salt Lake City, Utah, United States
|
|
| 99 |
NCT03424733 |
Recruiting |
Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects |
|
- Drug: Plegridy
- Drug: Prednisone
- Drug: Tylenol Pill
|
Interventional
|
Phase 4 |
- Holy Name Medical Center, Inc.
- Biogen
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Flu-like symptoms
- Injection site reactions
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT03424733 |
US-PEG-16-10990 |
|
September 25, 2017 |
June 1, 2018 |
July 1, 2018 |
February 7, 2018 |
February 7, 2018 |
|
- Holy Name Medical Center
Teaneck, New Jersey, United States
|
|
| 100 |
NCT01385228 |
Completed |
Pazopanib, Docetaxel, Prednisone Prostate |
|
- Drug: Pazopanib
- Drug: Docetaxel
- Drug: Prednisone
- Drug: Pegfilgrastim
|
Interventional
|
Phase 1 |
- Daniel George, MD
- GlaxoSmithKline
- Duke University
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number and Percent of Participants with Adverse Events as a Measure of Safety and Tolerability
- Establish the maximum tolerated dose
- Establish the optimal dosing schedule
|
36 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01385228 |
Pro00026577
PZP113296
c09-039 |
|
June 2011 |
July 2015 |
February 2016 |
June 30, 2011 |
June 6, 2018 |
|
- The University of Chicago
Chicago, Illinois, United States - Duke Cancer Institute
Durham, North Carolina, United States
|
|
Create an RSS feed from your search for:
Download the search results for: